PRO ACT
PHARMACY BENEFIT MANAGEMENT

1230 US Highway 11
Gouverneur, NY 13642
Phone: 1-877-635-9545
Prior Authorization Fax: 1-844-712-8129

Enbrel® Prior Authorization Request Form (Page 1 of 2)

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
❑ Check if requesting **brand**	Directions for Use:	
❑ Check if request is for **continuation of therapy**		

Clinical Information (required)

Select the diagnosis below:

- ❑ Active ankylosing spondylitis
- ❑ Active psoriatic arthritis (PsA)
- ❑ Moderate to severe chronic plaque psoriasis
- ❑ Moderately to severely active polyarticular juvenile idiopathic arthritis (PJIA)
- ❑ Moderately to severely active rheumatoid arthritis (RA)
- ❑ Other diagnosis:_____ICD-10 Code(s): _____

Clinical Information:

Is this request for continuation of prior Enbrel therapy? ❑ **Yes** ❑ **No**

Select if Enbrel will be used in combination with the following**:**

- ❑ Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept)]
- ❑ Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- ❑ Phosphodiesterase 4 (PDE 4) inhibitor [e.g., Otezla (apremilast)]
- ❑ Not in combination with a biologic DMARD, janus kinase inhibitor, or PDE4 inhibitor

Select if Enbrel is prescribed by or in consultation with one of the following specialists:

- ❑ Dermatologist
- ❑ Rheumatologist

Select if the patient has history of failure, contraindication, or intolerance to the following, if applicable for the patient's diagnosis:

- ❑ Cimzia (certolizumab)
- ❑ Humira (adalimumab)
- ❑ Simponi (golimumab) or Simponi Aria (golimumab IV)
- ❑ Stelara (ustekinumab)
- ❑ Taltz (ixekizumab)

For active ankylosing spondylitis, also answer the following:

Does the patient have history of failure, contraindication, or intolerance to two non-steroidal anti-inflammatory drugs (NSAIDs)? ❑ **Yes** ❑ **No**

For moderately to severely active polyarticular juvenile idiopathic arthritis (PJIA), also answer the following:

Does the patient have history of failure, contraindication, or intolerance to Arava (lefunomide) **OR** Rheumatrex/Trexall (methotrexate)? ❑ **Yes** ❑ **No**

For moderately to severely active rheumatoid arthritis (RA), also answer the following:

Does the patient have history of failure, contraindication, or intolerance to one non-biologic disease modifying anti-rheumatic drug (DMARD) [e.g., Rheumatrex/Trexall (methotrexate), Arava (leflunomide), Azulfidine (sulfasalazine)]? ❑ **Yes** ❑ **No**

1230 US Highway 11
Gouverneur, NY 13642
Phone: 1-877-635-9545
Prior Authorization Fax: 1-844-712-8129

Enbrel® Prior Authorization Request Form (Page 2 of 2)

Reauthorization:
If this is a reauthorization request, answer the following questions:

Is there documentation the patient has had a positive clinical response to Enbrel therapy? ❑ **Yes** ❑ **No**

Select if Enbrel will be used in combination with the following**:**

- ❑ Biologic DMARD [e.g., Humira (adalimumab), Cimzia (certolizumab), Simponi (golimumab), Orencia (abatacept)]
- ❑ Janus kinase inhibitor [e.g., Xeljanz (tofacitinib)]
- ❑ Phosphodiesterase 4 (PDE 4) inhibitor [e.g., Otezla (apremilast)]
- ❑ Not in combination with a biologic DMARD, janus kinase inhibitor, or PDE4 inhibitor

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: This request may be denied unless all required information is received.

Please fax this form to 1-844-712-8129 to initiate a prior authorization review for the member and medication above.

Please note: plan benefits may limit or exclude coverage of specific medications including those requested on this form.

I certify, to the best of my knowledge, the statements and information provided on this form are factual and correct.

Provider/Representative (and Title): _____ **Date:** _____

PROACT INTERNAL USE ONLY:					
Clinical Review Decision					
	Approved, through				
	Denied (documentation attached, if necessary)				
Tracking:					
1st Attempt		2nd Attempt		Letter Mailed:	